Research progress on pharmacokinetic interactions of sodium-glu-cose co-transporter 2 inhibitors
10.12092/j.issn.1009-2501.2025.04.016
- VernacularTitle:钠-葡萄糖共转运蛋白2抑制剂药动学相互作用研究进展
- Author:
Yanru DENG
1
;
Gexi CAO
;
Ying LI
;
Yajing LI
;
Zhanjun DONG
Author Information
1. 河北医科大学药学院,石家庄 050017,河北;河北省人民医院药学部,石家庄 050051,河北
- Publication Type:Journal Article
- Keywords:
sodium-glucose co-transporter 2 in-hibitors;
pharmacokinetics;
drug-drug interaction;
uridine diphosphate glucuronosyltransferase;
trans-porter
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(4):570-576
- CountryChina
- Language:Chinese
-
Abstract:
Sodium-glucose co-transporter 2(SGLT2)inhibitors are a new class of oral hypoglyce-mic drugs with definite hypoglycemic effects,low risk of hypoglycemia,cardiovascular protection,and kidney benefits.In recent years,SGLT2 inhibi-tors have been widely used in clinical practice,and their interactions with other drugs have gradually attracted attention.The SGLT2 inhibitors commonly used in China's clinic include canagliflozin,dapa-gliflozin,empagliflozin,ertugliflozin and hena-gliflozin currently,they are mainly metabolized by the phase Ⅱ metabolic enzyme uridine diphos-phate glucuronosyltransferase(UGT),and various transporters are involved in the disposal of SGLT2 inhibitors in vivo.This article reviews the pharma-cokinetic characteristics of different SGLT2 inhibi-tors mentioned above,as well as their pharmacoki-netic interaction studies with various drugs such as statins,antineoplastic drugs,antimicrobials,nonste-roidal anti-inflammatory drugs and traditional Chi-nese medicine,in order to promote the safe and ra-tional use of SGLT2 inhibitors in clinical practice.
